Understanding Biopiracy and Its Threat to Indigenous Knowledge

Every time a pharmaceutical company patents a remedy that indigenous communities have used for generations, something deeply unjust occurs – not just economically, but culturally and ethically. This practice is called biopiracy, and it sits at the uncomfortable intersection of intellectual property law, biodiversity conservation, and colonial history. Understanding how biopiracy operates, where it has occurred, and what the world is doing to stop it is essential for anyone invested in fair and sustainable relationships between science and indigenous communities.

What is biopiracy? 🔗

Biopiracy is broadly defined as “the unauthorized extraction of biological resources and/or associated traditional knowledge from developing countries, or the patenting of spurious inventions based on such knowledge or resources without compensation.” In plain terms, it happens when corporations, researchers, or institutions take plants, genetic material, or indigenous knowledge – developed and preserved over centuries – and commercialize them without seeking consent or sharing the resulting profits with the communities of origin.

The term itself was coined in the 1990s by environmentalists and NGOs who noticed a troubling pattern: corporations were filing patents in Western legal systems for “discoveries” that were, in reality, long-standing knowledge held by communities in the Global South. Biopiracy has been called “a silent disease” because it rarely leaves visible traces and is far less reported in media compared to environmental issues like deforestation, despite causing significant harm.

What makes biopiracy particularly damaging is its economic scale. The annual global market value of pharmaceutical products derived from medicinal plants identified by indigenous peoples exceeds US$43 billion – yet the communities whose knowledge led to those products rarely receive any share of that value.

Notable cases of biopiracy 🔗

The most instructive examples of biopiracy come from India, where several widely-used traditional remedies became the subject of foreign patents – without the knowledge or consent of the communities that developed them.

The turmeric patent 🔗

In 1995, the US Patent and Trademark Office (USPTO) granted a patent to researchers at the University of Mississippi Medical Center for using turmeric in wound healing – a practice documented in Indian Ayurvedic medicine for thousands of years. The Indian Council of Scientific and Industrial Research (CSIR) challenged the patent by submitting 32 references from ancient Sanskrit, Hindi, and Urdu texts, along with modern scientific literature, as evidence of prior art. The USPTO revoked the patent in 1997, acknowledging that the use of turmeric for wound healing was “an old art.” This case became a landmark in the global fight against biopiracy and demonstrated that documented traditional knowledge could successfully challenge unjust patents.

The neem patent 🔗

The neem tree (Azadirachta indica), long known in India as a “village pharmacy,” became the subject of another major biopiracy dispute. The European Patent Office granted a patent to W.R. Grace (a US company) and the US Department of Agriculture for a method of extracting neem oil for use as a pesticide – a method already well-known in Indian agricultural practice for centuries. After a prolonged international legal battle, the European Patent Office revoked the patent in 2000. Unlike the turmeric case, the neem dispute took much longer, largely because India lacked a readily accessible global documentation of its traditional knowledge at the time.

These cases are not isolated incidents. Indian products such as tamarind, Darjeeling tea, and basmati rice have all been subject to foreign patent or trademark claims, illustrating how broad the reach of biopiracy can be – extending well beyond medicine into agriculture and food.

Legal protections against biopiracy 🔗

In response to growing global concern, a range of international and national legal frameworks have been developed to address biopiracy and protect both biological resources and the indigenous knowledge systems associated with them.

The Convention on Biological Diversity (CBD) 🔗

The Convention on Biological Diversity, which entered into force in 1992, gives countries sovereign rights over their biological resources. Its Article 8(j) specifically requires member states to respect, preserve, and maintain the knowledge of indigenous and local communities, and to promote the equitable sharing of benefits arising from the use of that knowledge. The CBD introduced the concept of Access and Benefit Sharing (ABS), which requires anyone seeking to use a country’s genetic resources or traditional knowledge to first obtain prior informed consent and agree on fair compensation.

The Nagoya Protocol 🔗

The CBD’s ABS provisions were significantly strengthened by the Nagoya Protocol, adopted in 2010. From a practical standpoint, it gives each country sovereignty over its biological resources and makes unauthorized commercial use – biopiracy – explicitly illegal under international law. The Protocol covers both genetic resources and the traditional knowledge associated with them, providing clearer legal mechanisms for ensuring communities receive fair compensation when their knowledge is used commercially.

India’s Traditional Knowledge Digital Library (TKDL) 🔗

On a national level, one of the most effective tools developed to counter biopiracy is India’s Traditional Knowledge Digital Library (TKDL), established after the neem and turmeric disputes. It is a searchable database of traditional Indian medicinal knowledge – drawn from Ayurveda, Unani, Siddha, and other systems – formatted in ways that patent examiners around the world can access and use in prior art searches. Patent offices in Europe, the United States, Australia, and other countries have been granted access to TKDL. This shifts the burden of proof: instead of waiting for a patent to be granted and then fighting to revoke it, the database helps prevent the patent from being issued in the first place.

Additionally, India’s Patents Act, 1970, under Section 3(p), classifies traditional knowledge as a non-invention, barring it from patent protection – providing a domestic legal barrier against domestic biopiracy claims as well.

Ensuring fair compensation and recognition 🔗

While legal frameworks provide essential safeguards, the more transformative challenge is building models that proactively recognize indigenous contributions and ensure communities actually benefit from the commercialization of their knowledge. One of the most studied examples of this comes from Kerala, India.

The Kani tribe and Arogyapacha: a benefit-sharing model 🔗

During a botanical expedition in 1987, scientists from the Tropical Botanic Garden and Research Institute (TBGRI) observed members of the Kani tribe eating fruits from a plant they called Arogyapacha (Trichopus zeylanicus), meaning “the green that gives strength.” The Kani had traditionally used this plant to combat fatigue on long, grueling treks through the forest. TBGRI researchers studied the plant and developed an herbal formulation called Jeevani, marketed as an anti-fatigue and immunoenhancing product.

What made this case stand out was the deliberate decision to recognize and compensate the Kani tribe from the outset. A benefit-sharing agreement was established that provided the community with a percentage of the licensing fees and royalties from Jeevani’s commercialization. The Kerala Kani Samudaya Kshema Trust was set up to administer the funds on behalf of the tribe. This case drew international attention as a model of what ethical bioprospecting – the legal and respectful counterpart to biopiracy – could look like in practice.

The Jeevani-Kani case also had a broader policy impact. It catalyzed several significant legal reforms in India and influenced discussions under the Convention on Biological Diversity and the Nagoya Protocol at a global scale, reinforcing the importance of prior informed consent and community partnerships in biodiversity research.

Limitations of the model 🔗

The Kani case, however, is not without criticism. The benefit-sharing agreement had shortcomings, including the failure to include tribal informants as co-inventors in the patent application. Many Kani members also reported feeling inadequately consulted during the negotiation process. Distribution of funds within Kani settlements was uneven, and when Jeevani’s patent expired in 2008, the tribe lost even the limited IP-backed protections it had enjoyed. These gaps highlight a consistent challenge: the difference between a benefit-sharing agreement that exists on paper and one that delivers sustained, equitable outcomes to communities on the ground.

Despite its flaws, the Jeevani-Kani model remains significant. It demonstrated that the relationship between scientific research and indigenous knowledge does not have to be exploitative. When communities are treated as partners – not just sources of raw data – knowledge can be shared in ways that are both scientifically productive and socially just.

The broader challenge 🔗

Biopiracy persists because the global intellectual property system was not designed with indigenous knowledge in mind. Patents are built on criteria of novelty and non-obviousness – standards that effectively erase centuries of collective innovation by treating indigenous practices as if they exist in a legal vacuum. As long as traditional knowledge is not formally recognized as intellectual property in its own right, it remains vulnerable.

Progress is being made. WIPO published a Toolkit to document traditional knowledge in 2017. Community protocols that formalize how indigenous groups give consent and control access to their knowledge are gaining traction. And countries like Peru and Bolivia have adopted sui generis legal systems that recognize collective ownership of traditional knowledge, allowing communities to license and earn royalties from products derived from it. These models point toward what a fairer global system might look like.

What do you think? When a pharmaceutical company develops a drug based on a plant remedy used by an indigenous community for centuries, who should hold the intellectual property rights – the community, the researchers, or both? And do you think digital libraries like India’s TKDL go far enough in protecting traditional knowledge, or is a more fundamental reform of the global patent system needed?

References

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC7910072/
2. https://www.cbd.int/abs/doc/protocol/icnp-1/joint-submission-grand-council-and-others-en.pdf
3. https://www.lexology.com/library/detail.aspx?g=1c132aa5-97af-4164-af22-ca3c240ab172
4. https://www.taxtmi.com/article/detailed?id=14431
5. https://theconversation.com/biopiracy-when-indigenous-knowledge-is-patented-for-profit-55589
6. https://en.wikipedia.org/wiki/Nagoya_Protocol
7. https://satyakilegal.com/beyond-biopiracy-analysing-the-jeevani-kani-tribe-benefit-sharing-model-and-its-implications-for-traditional-knowledge-governance-in-india/
8. https://journal.cdipr.ac.in/index.php/jdipr/article/view/3